Affimed (AFMD)
(Delayed Data from NSDQ)
$3.69 USD
-0.27 (-6.82%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.70 +0.01 (0.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Affimed N.V. [AFMD]
Reports for Purchase
Showing records 1 - 15 ( 15 total )
Company: Affimed N.V.
Industry: Medical - Drugs
New Data Showcase Potential of Innate Cell Engagers Across Liquid and Solid Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Affimed N.V.
Industry: Medical - Drugs
AFM24?s Promising Potential in Late-Line mNSCLC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Affimed N.V.
Industry: Medical - Drugs
Positive Trend Continues for AFM24; Catalyst-rich 2Q24; New PT $10; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Affimed N.V.
Industry: Medical - Drugs
Positive Acimtamig Update Bodes Well For LuminICE-203
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Affimed N.V.
Industry: Medical - Drugs
Targeting Accelerated Approval; Major Clinical Readouts in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Affimed N.V.
Industry: Medical - Drugs
Programs Progressing to Yield a Data-Rich 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Affimed N.V.
Industry: Medical - Drugs
ASCO Data Highlights Monotherapy Potential of AFM24 in NSCLC; Adjusting PT Down to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Affimed N.V.
Industry: Medical - Drugs
LuminICE-203 to Test the Potential of AFM13+AB-101; AFM24-101 Data at ASCO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Affimed N.V.
Industry: Medical - Drugs
AFM24 Clinical Data Updates Expected in Mid-2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Affimed N.V.
Industry: Medical - Drugs
Key Takeaways From Our Fireside Chat with Dr. Michael Bishop on AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Affimed N.V.
Industry: Medical - Drugs
Multiple Myeloma Landscape - CD38, BCMA, GPRC5D, and FcRH5 (Version 1.0)
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Affimed N.V.
Industry: Medical - Drugs
High Affinity Innate Cell Engagers Like No Others; Initiate With Buy and a $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Affimed N.V.
Industry: Medical - Drugs
Company: Affimed N.V.
Industry: Medical - Drugs
Healthcare -CD33 Targeting in AML: Three Takeaways from ASH
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Affimed N.V.
Industry: Medical - Drugs
|